Skip to main content
TipRanks
Go Ultimate75% OFF

Argenica Therapeutics Ltd (AGN) Share Price & Analysis

14 Followers

AGN Stock Chart & Stats

A$0.12-A$0.01(-7.69%)
At close: 4:00 PM GMT+11
AU$0.1AU$0.15AU$0.2Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
AUD 0.12 - AUD 0.13
52-Week Range
AUD 0.09 - AUD 0.35
Previous Close
AUD 0.13
Volume
N/A
Average Volume (3M)
58.38K
Market Cap
AUD 16.70M
Enterprise Value
AUD 32.86M
Total Cash (Recent Filing)
AUD 6.36M
Total Debt (Recent Filing)
AUD 0
Price to Earnings (P/E)
―
Beta
1.48
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

Zero debt limits leverage and refinancing pressure, giving Argenica greater flexibility while it advances its development programs. This can preserve strategic options and reduce fixed financial obligations, although the balance sheet remains exposed to operating losses and future funding needs.

Focused Neuroprotective Pipeline

A focused pipeline targeting serious neurological injuries gives Argenica a clear therapeutic purpose and aligns development resources around high-impact unmet needs. Progress in these programs could create meaningful product value if clinical development ultimately demonstrates improved outcomes.

Prior Revenue Expansion

The increase in reported revenue through 2025 indicates that Argenica had previously established some commercial or partnering activity before the 2026 interruption. That history provides evidence of potential revenue generation, though its durability remains unproven.

Bears Say

Persistent Operating Cash Burn

Sustained negative operating cash flow means the business is not funding its activities internally and remains reliant on available capital or future financing. Continued burn can reduce financial flexibility and may force funding decisions before development milestones are reached.

Revenue Volatility And Zero 2026 Revenue

The sharp revenue reversal demonstrates that reported income is highly volatile and that prior revenue growth has not yet become a dependable base. Unpredictable commercial inflows make planning harder and increase dependence on financing while the pipeline remains in development.

Recurring Losses And Weak Returns

Recurring operating and net losses show that Argenica has not yet reached sustainable profitability, while negative returns indicate shareholder capital is not currently producing earnings. This limits internally funded growth and leaves future value dependent on successful development and commercialization.

Argenica Therapeutics Ltd News

AGN FAQ

What was Argenica Therapeutics Ltd’s price range in the past 12 months?
Argenica Therapeutics Ltd lowest share price was AU$0.09 and its highest was AU$0.35 in the past 12 months.
What is Argenica Therapeutics Ltd’s market cap?
Argenica Therapeutics Ltd’s market cap is AU$16.70M.
When is Argenica Therapeutics Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Argenica Therapeutics Ltd’s earnings last quarter?
Argenica Therapeutics Ltd released its earnings results on Feb 10, 2026. The company reported -AU$0.03 earnings per share for the quarter.
Is Argenica Therapeutics Ltd overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Argenica Therapeutics Ltd pay dividends?
Argenica Therapeutics Ltd does not currently pay dividends.
What is Argenica Therapeutics Ltd’s EPS estimate?
Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argenica Therapeutics Ltd have?
Argenica Therapeutics Ltd has 128,456,710 shares outstanding.
What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?
Argenica Therapeutics Ltd reported an EPS of -AU$0.03 in its last earnings report. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?
Currently, no hedge funds are holding shares in AU:AGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology